We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (103)11/20/2002 2:01:28 PM
From: scaram(o)uche  Read Replies (1) of 146
J Pharmacol Exp Ther 2002 Dec 1;303(3):1189-1198

SSR182289A, a Novel, Orally Active Thrombin Inhibitor: In Vitro Profile and ex Vivo Anticoagulant Activity.

Berry CN, Lassalle G, Lunven C, Altenburger JM, Guilbert F, Lale A, Herault JP, Lecoffre C, Pfersdorff C, Herbert JM, O'Connor SE.

Sanofi-Synthelabo Research, Cardiovascular-Thrombosis Department, Chilly-Mazarin and Toulouse, France.

SSR182289A competitively inhibits human thrombin (K(i) = 0.031 +/- 0.002 &mgr;M) and shows good selectivity with respect to other human proteases, e.g., trypsin (K(i) = 54 +/- 2 &mgr;M), factor Xa (K(i) = 167 +/- 9 &mgr;M), and factor VIIa, factor IXa, plasmin, urokinase, tPA, kallikrein, and activated protein C (all K(i) values >250 &mgr;M). In human plasma, SSR182289A demonstrated anticoagulant activity in vitro as measured by standard clotting parameters (EC(100) thrombin time 96 +/- 7 nM) and inhibited tissue factor-induced thrombin generation (IC(50) of 0.15 +/- 0.02 &mgr;M). SSR182289A inhibited thrombin-induced aggregation of human platelets with an IC(50) value of 32 +/- 9 nM, but had no effect on aggregation induced by other platelet agonists. The anticoagulant effects of SSR182289A were studied by measuring changes in coagulation markers ex vivo after i.v. or oral administration in several species. In dogs, SSR182289A (0.1-1 mg/kg i.v. and 1-5 mg/kg p.o.) produced dose-related increases in clotting times. After oral dosing, maximum anticoagulant effects were observed 2 h after administration with increases in thrombin time, 2496 +/- 356%; ecarin clotting time (ECT), 1134 +/- 204%; and activated partial thromboplastin time (aPTT), 91 +/- 20% for the dose of 3 mg/kg p.o., and thrombin time, 3194 +/- 425%; ECT, 2017 +/- 341%; and aPTT, 113 +/- 9% after 5 mg/kg p.o. Eight hours after administration of 3 or 5 mg/kg SSR182289A, clotting times were still elevated. SSR182289A also showed oral anticoagulant activity in rat, rabbit, and macaque. Hence, SSR182289A is a potent, selective, and orally active thrombin inhibitor.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext